Biogen Inc (NASDAQ:BIIB)

284.41
Delayed Data
As of May 24
 +0.66 / +0.23%
Today’s Change
244.28
Today|||52-Week Range
370.57
-10.72%
Year-to-Date
SECTOR
Health Technology
INDUSTRY
Biotechnology
MARKET CAP
$59.6B

Company Description

Biogen, Inc. is a biopharmaceutical company, which engages in discovering, developing, and delivering therapies for neurological and neurodegenerative diseases. It offers TECFIDERA, AVONEX, PLEGRIDY, TYSABRI, ZINBRYTA, and FAMPYRA for the treatment of multiple sclerosis; SPINRAZA for the treatment of spinal muscular atrophy; and FUMADERM for the treatment of severe plaque psoriasis. The company was founded by Charles Weissmann, Heinz Schaller, Kenneth Murray, Walter Gilbert, and Phillip Allen Sharp in 1978 and is headquartered in Cambridge, MA.

Contact Information

Biogen, Inc.
225 Binney Street
Cambridge Massachusetts 02142
P:(617) 679-2000
Investor Relations:

Employees

Shareholders

Mutual fund holders53.16%
Other institutional38.58%
Individual stakeholders1.54%

Top Executives

Michel VounatsosChief Executive Officer & Director
Jeffrey D. CapelloChief Financial Officer & Executive Vice President
Alfred W. SandrockChief Medical Officer & Executive Vice President
Mark HernonChief Information Officer & Senior Vice President
Michael D. EhlersExecutive VP-Research & Development